Use of Artificial Intelligence and Machine Learning in Rapid Drug Discovery and Pharmacovigilance

The increasing global burden of disease, rising research and development costs, and high attrition rates in pharmaceutical pipelines underscore the need for more efficient approaches to therapeutic development and drug safety monitoring. Artificial intelligence (AI) and machine learning (ML) have emerged as data-driven tools with the potential to improve multiple stages of the pharmaceutical lifecycle. This narrative review is designed to provide a structured and critical overview of the use of AI and ML in drug discovery and drug safety surveillance. A comprehensive literature search was performed to identify relevant studies using major electronic databases, with emphasis on publications from 1997 to March 2025. The studies were selected based on the inclusion criteria. The findings of the study show that AI and ML are being used in drug discovery, drug development, and drug safety surveillance. These technologies have the potential to provide predictive models, integrate heterogeneous biomedical data, and analyze real-world data to detect adverse drug reactions. Deep learning and natural language processing have been found to be useful tools to improve early risk detection. However, some limitations have also been found. These include the quality of the data, bias in AI and ML models, lack of interpretability of AI and ML models, lack of external validation, and lack of real-world implementation. These limitations need to be addressed to make AI and ML more useful tools for drug discovery and drug safety surveillance. Overall, while AI and ML offer meaningful opportunities to enhance drug discovery and pharmacovigilance, their impact remains dependent on rigorous validation, improved data governance, and alignment with clinical and regulatory frameworks. Continued research and context-specific implementation strategies will be essential to support their effective and equitable integration into pharmaceutical research and healthcare systems.

Authors

Institutions

Publication Details

Journal
Journal of international research in medical and pharmaceutical sciences
Published
2026-04-23
DOI
https://doi.org/10.56557/jirmeps/2026/v21i210521
Primary Topic
Pharmacovigilance and Adverse Drug Reactions
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Use of Artificial Intelligence and Machine Learning in Rapid Drug Discovery and Pharmacovigilance

Uchechukwu Lilian Okoye, Isaac Baiden, Adepeju Kafayat Olowookere, Olukunle O. Akanbi et al.
Journal of international research in medical and pharmaceutical sciences
Pharmacovigilance and Adverse Drug Reactions
article

Use of Artificial Intelligence and Machine Learning in Rapid Drug Discovery and Pharmacovigilance

Uchechukwu Lilian Okoye, Isaac Baiden, Adepeju Kafayat Olowookere, Olukunle O. Akanbi, Ndidi Atasie Eboh, Faith Chinaza Ngwoke, Akinlolu Oluwamisimi, Ogboh Rita Onyebuchi, Onodje Lucky
article en

Abstract

The increasing global burden of disease, rising research and development costs, and high attrition rates in pharmaceutical pipelines underscore the need for more efficient approaches to therapeutic development and drug safety monitoring. Artificial intelligence (AI) and machine learning (ML) have emerged as data-driven tools with the potential to improve multiple stages of the pharmaceutical lifecycle. This narrative review is designed to provide a structured and critical overview of the use of AI and ML in drug discovery and drug safety surveillance. A comprehensive literature search was performed to identify relevant studies using major electronic databases, with emphasis on publications from 1997 to March 2025. The studies were selected based on the inclusion criteria. The findings of the study show that AI and ML are being used in drug discovery, drug development, and drug safety surveillance. These technologies have the potential to provide predictive models, integrate heterogeneous biomedical data, and analyze real-world data to detect adverse drug reactions. Deep learning and natural language processing have been found to be useful tools to improve early risk detection. However, some limitations have also been found. These include the quality of the data, bias in AI and ML models, lack of interpretability of AI and ML models, lack of external validation, and lack of real-world implementation. These limitations need to be addressed to make AI and ML more useful tools for drug discovery and drug safety surveillance. Overall, while AI and ML offer meaningful opportunities to enhance drug discovery and pharmacovigilance, their impact remains dependent on rigorous validation, improved data governance, and alignment with clinical and regulatory frameworks. Continued research and context-specific implementation strategies will be essential to support their effective and equitable integration into pharmaceutical research and healthcare systems.

Journal of international research in medical and pharmaceutical sciencesVol. 21(2)
Manchester Metropolitan University (GB), Alliant International University (US), Johns Hopkins University (US), Niger Delta University (NG), University of North Carolina at Greensboro (US), Wayne State University (US), National Louis University (US), Johns Hopkins Medicine (US), Stark State College (US), Georgia Southern University (US), United States International University Africa (KE)
Openalex Percentile: Top 18%
Pharmacovigilance and Adverse Drug Reactions
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.